Pulnovo Medical, a globally recognized device pioneer in the treatment for pulmonary hypertension and heart failure, recently completed a series of landmark events across Europe, further advancing its global outreach and strengthening its leadership in the field. From September 13 to 18, 2024, Pulnovo successfully conducted a live broadcast of percutaneous pulmonary artery denervation (PADN) surgery in Serbia and held a prestigious PADN Master Class in Portugal, underscoring the company’s commitment to driving international collaboration and shaping the future of pulmonary hypertension (PH) treatment.

During the SINERGY 2024 conference in Serbia, the team led by Professor Shaoliang Chen from Nanjing Medical University Affiliated Nanjing Hospital performed a PADN surgery broadcast to a global audience. This real-time demonstration provided an in-depth view of PADN’s clinical advantages in treating pulmonary hypertension, offering medical professionals worldwide an invaluable opportunity to observe the cutting-edge technology in action.

Pulnovo Medical also hosted its first PADN Master Class in Portugal in September 18. This groundbreaking course provided a platform for cardiovascular and pulmonary hypertension specialists from German, Italy, Portugal, Greece and so on to engage in comprehensive discussions, hands-on case demonstrations, and refine their procedural techniques. Designed to enhance participants' understanding of PADN, the Master Class aimed to accelerate the adoption of this innovative technology in clinical practice across the world.

About PADN

Pulmonary Artery Denervation (PADN) is a percutaneous pulmonary artery intervention procedure that uses a PADN catheter to deliver radiofrequency energy to the sympathetic nerves in the outer membrane of the pulmonary artery, resulting in the disappearance of the myelin sheath of the nerves and the fusion of the axons, which inhibits sympathetic activity, increases cardiac output, reduces pulmonary artery pressure , inhibits the pathologic remodeling of the pulmonary arteries, improves the patient's exercise endurance and cardiac function, and achieves long-term benefits from a single minimally invasive procedure.

About Pulnovo Medical

Pulnovo Medical Limited, is a globally recognized device pioneer in the treatment for pulmonary hypertension and heart failure. Established in 2013 and rooted in innovation, Pulnovo Medical is committed to leveraging our deep expertise in the science of breakthrough technologie with the goal to market our innovative therapeutic solutions and benefit patients around the world.